Background: Transcutaneous electrogastrography is a novel modality to assess the human stomach’s gastric myoelectrical activity. The
purpose of this study was to compare functional dyspepsia, joint hypermobility, and diabetic gastroparesis patients with healthy control
subjects in terms of gastric motility abnormalities through electrogastrography evaluations, and to then evaluate the correlation among
variations in their blood parameters.
Methods: This study analyzed 120 subjects with functional dyspepsia (n = 30), joint hypermobility (n = 30), diabetic gastroparesis
(n = 30), and control subjects (n = 30). The electrogastrography parameters included the dominant frequency, dominant power, power
ratio, and instability coefficient, which were analyzed preprandially and postprandially. Although there are similar studies in the literature, there is no other study in which all groups have been studied together, as in our study.
Results: The electrogastrography results showed that preprandial dominant frequency (P = .031*), dominant power (P = .047*), and
instability coefficient (P = .043*), and postprandial dominant frequency (P = .041*) and dominant power (P = .035*) results were statistically significant among the functional dyspepsia, joint hypermobility, diabetic gastroparesis, and control groups.
There was no significant difference found in terms of power ratio (P = .114) values. However, only glucose (P = .04*) and calcium (P = .04*)
levels showed statistical significance. Several blood tests including hemoglobin (P = .032*), creatinine (P= .045*), calcium (P = .037*),
potassium (P= .041*), white blood cells (P = .038*), and alanine aminotransferase (P = .031*) also showed correlation with the dominant
frequency, power ratio, and instability coefficient parameters.
Conclusions: This joint methodology demonstrated that it is possible to differentiate between functional dyspepsia, joint hypermobility, and diabetic gastroparesis patients from healthy subjects by using electrogastrography. Moreover, the majority of patients showed
adequate gastric motility in response to food.
|
|
|
Mustafa KAPLAN, Arif KARAKAYA, Alpaslan TANOĞLU, Muhammet YILDIRIM, Yeşim Önal TAŞTAN, Zafer ÇIRAK, Zafer KÜÇÜKODACI
Mustafa KAPLAN, Arif KARAKAYA, Alpaslan TANOĞLU, Muhammet YILDIRIM, Yeşim Önal TAŞTAN, Zafer ÇIRAK,
... Devamını oku
Background: It was aimed to evaluate the preventive efficacy of trimetazidine in an experimental chronic pancreatitis rat model.
Methods: Chronic pancreatitis model was accomplished with caerulein and alcohol administration. In the study, 40 female Sprague
Dawley rats were randomized into 5 groups containing 8 animals in each. Group 1 (chronic pancreatitis); group 2 (chronic pancreati-
tis + low-dose trimetazidine group); group 3 (chronic pancreatitis + high-dose trimetazidine group); group 4 (placebo group (chronic
pancreatitis + saline)); group 5 (sham group). 24 hours after the last injection, all animals were sacrificed. Tumor necrosis factor-alpha,
transforming growth factor-β, malondialdehyde, and glutathione peroxidase levels were tested in blood samples. Histopathologic exam-
inations were conducted by a senior pathologist who was unaware of the group allocations.
Results: Results of biochemical parameters of the trimetazidine groups (groups 2 and 3) were significantly favorable compared with the
chronic pancreatitis group (group 1) (P < .05). The difference between the low-dose- and the high-dose trimetazidine group (group 3)
was significant in terms of blood tests (P < .05). The difference between the low-dose trimetazidine group and the chronic pancreatitis
group was not significant in terms of histopathologic scores (P > .05); however, the difference was significant between the high-dose
trimetazidine group and the chronic pancreatitis group (P < .05).
Conclusions: To the best of our knowledge, this current research is the first study that evaluates trimetazidine’s efficacy in the chronic
pancreatitis rat model. Trimetazidine has affirmative preventive properties in the chronic pancreatitis course.
|
Ramazan KOZAN, Ahmet Cihangir EMRAL, Can ŞAHİN, Pınar ÇAKMAK, Abdülkadir Bülent AYTAÇ
Ramazan KOZAN, Ahmet Cihangir EMRAL, Can ŞAHİN, Pınar ÇAKMAK, Abdülkadir Bülent AYTAÇ
|
Volkan GÖKBULUT, Bülent ÖDEMİŞ, Ömer ÖZTÜRK, Bülent YAMAK, İlyas TENLİK, Selcen Yüsra ABAYL, Handan ÖZTÜRK
Volkan GÖKBULUT, Bülent ÖDEMİŞ, Ömer ÖZTÜRK, Bülent YAMAK, İlyas TENLİK, Selcen Yüsra ABAYL,
... Devamını oku
|
Background: Cronkhite–Canada syndrome (CCS) is a disease of unknown etiology characterized by the presence of multiple gastrointestinal polyps, chronic diarrhea, loss of appetite, alopecia, onychodystrophy, and cutaneous hyperpigmentation. CCS is a rare disease
with an incidence rate of 1 per million. Clinicians are not aware of this disease, and the discovery of gastrointestinal polyps is often a
starting point for the diagnosis of this disease. By analyzing the endoscopic and pathological characteristics of CCS, this study aims to
deepen our understanding of gastrointestinal polyposis and facilitate early diagnosis of CCS.
Methods: We screened databases, including the Chinese Biomedical Literature Database (CBM Web), the China Academic Journals Fulltext Database (CJFD), and PubMed for CCS cases reported from January 2010 to January 2020, and conducted a retrospective analysis
of endoscopic and pathological characteristics of these cases.
Results: The endoscopic data of the 76 retrieved cases revealed that CCS is gastrointestinal polyposis with the intensive and confluent distribution. The greater the number of polyps and the higher their distribution, the brighter their color. A pathological assessment
revealed that both gastric polyps and intestinal polyps are mainly juvenile hamartomatous polyps and have a high malignant transformation rate. Interstitial edema, eosinophil infiltration, and cystic dilation of glands are common features of CCS polyps, distinguishing
them from other gastrointestinal polyposis syndromes.
Conclusion: CCS is a polyp disease different from other gastrointestinal polyposis. Analysis of its endoscopic and pathological characteristics can contribute to the understanding and early diagnosis of the disease.
|
Background: We aimed to investigate the long-term effects of tenofovir disoproxil fumarate and entecavir treatment on bone mineral
density and evaluated the fracture risk assessment tool score in patients with chronic hepatitis B.
Methods: A total of 58 chronic hepatitis B patients treated with tenofovir disoproxil fumarate (n = 40) and entecavir (n = 18) were
included in this prospective study from 2012 to 2016. To evaluate bone mineral density, dual-X-ray absorptiometry, fracture risk assessment tool, and laboratory examinations were performed in all patients first at baseline and second at the end of the study.
Results: Age, sex, body mass index, fibrosis score, and viral load were similar in both groups. The mean follow-up was 33 months in the
tenofovir disoproxil fumarate group and 31 months in the entecavir group. In patients treated with entecavir, there was no statistically
significant difference between baseline and second bone mineral density including lumbar spine (L) and total hip T score. In patients
treated with tenofovir disoproxil fumarate, there was a significant difference in the second bone mineral density compared with baseline bone mineral density for L3 (P = .033) and the major fracture risk assessment tool score (P = .03). When patients were divided into
3 groups (normal bone mineral density, osteopenic, and osteoporotic), there was a significant increase in the number of osteopenic
patients in the total hip T score after tenofovir disoproxil fumarate treatment (P = .034).
Conclusion: Our results suggest a decrease in the bone mineral density for lumbar spine (L3), an increase in the number of patients with
hip osteopenia, and major fracture risk assessment tool score after long-term tenofovir disoproxil fumarate treatment in patients with
rechronic hepatitis B.
|
Background: Inflammation plays an important role in the development and progression of non-alcoholic steatohepatitis (NASH), and
NASH is a powerful driving force for the progression of fibrosis. The neutrophil-to-lymphocyte ratio (NLR) is a simple emerging indicator
of inflammation. We aimed to assess the potential association between NLR and histological severity of non-alcoholic fatty liver disease
(NAFLD).
Methods: This retrospective study consisted of 231 patients with biopsy-proven NAFLD in China from August 2017 to September 2019.
The steatosis, activity, and fibrosis scoring system were used to evaluate liver biopsy tissue.
Results: Of the 231 patients with NAFLD, advanced inflammatory activity was present in 43.3% and significant fibrosis in 25.5% of
patients. Multivariate logistic regression analysis showed NLR to be correlated with advanced inflammatory activity (Odds ratio (OR):
0.62, 95% CI: 0.42-0.94, P = .025) and significant fibrosis (OR: 0.57, 95% CI: 0.35-0.94, P = .028). The NLR was inversely associated with
the degree of steatosis, lobular inflammation and fibrosis (r = −0.16, P = .014; r = −0.15, P = .019; r = −0.13, P = .046, respectively), but
had no association with the severity of ballooning. The multivariate-adjusted models had good predictability for advanced inflammatory
activity (area under curves (AUC) 0.790, 95% CI: 0.730-0.850) and for significant fibrosis (AUC 0.798, 95% CI: 0.728-0.868).
Conclusion: This study showed negative correlations between elevated NLR levels with advanced inflammatory activity and significant
fibrosis in patients with NAFLD. Our results also suggested that NLR could be considered as a simple and noninvasive mark to identify
high-risk populations in NAFLD.
|
Background: Some studies have reported the correlation between Helicobacter pylori and celiac disease (CD), but the results lack consistency. This meta-analysis aimed to quantify the relationship between H. pylori and CD. In addition, the study also analyzed the impact
of H. pylori on the symptoms and classification of CD.
Methods: Studies published up to September 1, 2020 on 3 databases – EMBASE, MEDICINE, and PubMed – were searched. The statistical
data of articles which met the requirements were collated and extracted.
Results: Twenty-five papers and 141 355 participants were finally enrolled. The results showed that the H. pylori infection rate of CD
patients was 0.57 times greater compared to controls (OR = 0.57, 95% CI [0.44, 0.75]), while statistical differences were also seen in the
subgroups of children (OR = 0.53, 95% CI [0.33, 0.85]) and adults (OR = 0.63, 95% CI [0.49, 0.81]). Furthermore, patients having CD with
H. pylori were more likely to have symptoms of abdominal pain, diarrhea, and distension (OR = 2.5, 95% CI [1.35, 4.62]) (OR = 1.56, 95%
CI [1.09, 2.24]) (OR = 2.75, 95% CI [1.74, 4.35]). However, H. pylori has no effect on CD classification.
Conclusion: The study confirmed that there is a correlation between H. pylori and CD, but the causality cannot be clarified. A demonstration of a causal role of H. pylori in CD in future prospective studies could have important therapeutic implications.
|
Background: The number of times that an article is cited could reflect its impact. This study aims to recognize and analyze the characteristics of the most frequently cited articles in the field of colorectal diseases.
Methods: We identified the 100 most-cited articles using the terms “colorectal,” “colon,” “rectal,” “IBD,” “ulcerative colitis,” “Crohn’s disease,” or “colonoscopy” in Web of Science. The articles were analyzed to evaluate the characteristics, including the number of citations,
country of origin, the institution of origin based on the first author’s affiliation, study type, and others.
Results: Of the top-cited publications, the number of citations ranged from 1575 to 9283, with a mean of 2504.11 citations. The journal
with the greatest number of most-cited articles was the New England Journal of Medicine (n = 23), followed by Science (n = 14) and
Nature (n = 12). These papers were published in 14 different countries, of which more than half were from the United States (n = 60).
The most popular field was colorectal cancer (n = 45), followed by colon tumors (n = 21). Most of the papers were basic science studies
(n = 43) and randomized controlled trials (n = 30). Regarding the level of evidence, there were 5 studies at level I, 29 at level II, and 5, 1,
and 15 studies at levels III, IV, and V, respectively.
Conclusion: Our study could provide a historical perspective on scientific progress in the field of colorectal diseases. These 100 mostcited articles are of great significance for helping researchers understand this field over time.
|
